GSK plc (LON:GSK) Receives Average Recommendation of “Hold” from Analysts

GSK plc (LON:GSK) has earned a consensus rating of “Hold” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is GBX 2,064.38.

Several brokerages recently commented on GSK. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a GBX 2,000 price target on shares of GSK in a research report on Tuesday, September 29th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,500 price target on shares of GSK in a research report on Wednesday, July 29th. Berenberg Bank upped their price objective on GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research note on Tuesday, September 15th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a GBX 1,975 price objective on shares of GSK in a report on Tuesday, September 8th.

GSK Price Performance

Shares of GSK stock opened at GBX 1,779.50 on Wednesday. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. GSK has a 1 year low of GBX 1,592 and a 1 year high of GBX 2,282. The firm’s fifty day moving average price is GBX 1,879.72 and its two-hundred day moving average price is GBX 1,940.33. The firm has a market capitalization of £71.30 billion, a P/E ratio of 15.11, a PEG ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK) last posted its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. On average, equities analysts predict that GSK will post 175.980975 EPS for the current fiscal year.

Insider Buying and Selling at GSK

In other news, insider Anne Beal acquired 637 shares of the firm’s stock in a transaction dated Friday, September 18th. The stock was bought at an average price of GBX 4,985 per share, with a total value of £31,754.45. Also, insider Jonathan Symonds acquired 1,500 shares of the stock in a transaction dated Friday, September 18th. The shares were purchased at an average price of GBX 1,881 per share, for a total transaction of £28,215. Insiders have acquired 2,144 shares of company stock worth $6,009,566 over the last ninety days. Insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.